About Sherlock Biosciences
Sherlock Biosciences is a company based in Watertown (United States) founded in 2019 by David Walt, Omar Abudayyeh, and Jonathan Gootenberg was acquired by OraSure in December 2024. It operates as a HealthTech. Sherlock Biosciences has raised $111 million across 8 funding rounds from investors including United States Department of Agriculture, Gates Foundation and OraSure Technologies. The company has 33 employees. Sherlock Biosciences has completed 1 acquisition, including Sense Biodetection. Sherlock Biosciences offers products and services including SHERLOCKâ„¢ and INSPECTRâ„¢. Sherlock Biosciences operates in a competitive market with competitors including GRAIL, Amyris, Syngenta, AskBio and Color, among others.
- Headquarter Watertown, United States
- Employees 33
- Founders David Walt, Omar Abudayyeh, Jonathan Gootenberg
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website sherlock.bio
- Social LinkedIn X Facebook Instagram
- Acquired by OraSure (Dec 2024)
- Legal Name Orasure Technologies, Inc.
- Total Equity Funding$111M (USD)
in 8 rounds
- Latest Funding Round$298.95K (USD), Grant
Aug 2024
- InvestorsUnited States Department of Agriculture
& 10 more
- Employee Count33
- Investments & Acquisitions
- Acquired byOraSure
(Dec 2024)
Products & Services of Sherlock Biosciences
Sherlock Biosciences offers a comprehensive portfolio of products and services, including SHERLOCK™ and INSPECTR™.
CRISPR-based tool for rapid DNA/RNA detection used.
Synthetic biology platform for affordable diagnostics developed.
Funding Insights of Sherlock Biosciences
Sherlock Biosciences has successfully raised a total of $111M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $298.95 thousand completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $111M
- Total Rounds 8
- Last Round Grant — $298,948
- First Round $31M
(Apr 2019)
- Investors Count 10
All 8 funding rounds of Sherlock Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $298,948 | Grant | – | – | |
| Jul 2023 | $174,957 | Grant | – | – | |
| Nov 2022 | $2M | Grant | – | – | |
| Mar 2022 | $80M | Series B | – | Novalis LifeSciences | |
| Dec 2020 | $5M | Grant | – | – | |
| May 2020 | $7.5M | Grant | – | – | |
| Apr 2019 | $31M | Series A | – | Baidu Ventures, Open Philanthropy | – |
| Apr 2019 | $17.5M | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Sherlock Biosciences
Sherlock Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include United States Department of Agriculture, Gates Foundation and OraSure Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
Health tech startups are invested in by Illumina Ventures. | – | illuminaventures.com | Foster City, United States | |
Investments in healthtech startups are made by Albany Capital. | – | albanycapital.com.au | - | |
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
Venture capital is provided to biomedical technology startups. | – | cataliocapital.com | New York, United States | |
Leadership is provided on agriculture, food, and rural development matters. | 1862 | usda.gov | - | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Philanthropic initiatives are supported to enable humanity's thriving. | – | goodventures.org | San Francisco, United States | |
Open Philanthropy is engaged in funding impactful global initiatives. | – | openphilanthropy.org | San Francisco, United States | |
- | – | bv.ai | - |
Investor details for Sherlock Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sherlock Biosciences
23 people are tracked at Sherlock Biosciences (12 in leadership, 6 in board & advisors, 5 in team); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
David Walt | Co-Founder | Leadership |
Omar Abudayyeh | Co-Founder | Leadership |
Jonathan Gootenberg | Co-Founder | Leadership |
Bryan Dechairo | CEO | Leadership |
Carrie Eglinton Manner | President & CEO | Leadership |
Kenneth J. McGrath | CFO | Leadership |
Kathleen Weber | Chief Product Officer | Leadership |
Rafal Iwasiow | VP, Science, Innovation & Technology | Leadership |
Michele Anthony | SVP, Controller & Chief Accounting Officer | Leadership |
Amy Lyons | VP Of Corporate Communications | Leadership |
Phylis Hetie | Associate Director - Head Of Intellectual Property | Leadership |
T S Ramasubramanian | Vice President, Assay Research And Development | Leadership |
Mara G. Aspinall | Chair | Board & advisors |
Nancy J. Gagliano | Director | Board & advisors |
Lelio Marmora | Director | Board & advisors |
David J. Shulkin | Director | Board & advisors |
Robert W. McMahon | Director | Board & advisors |
Jack Kenny | Director | Board & advisors |
David Rappaport | SVP, Corporate Development, Strategy & Integration | Team |
Stefano Taucer | General Counsel & Corporate Secretary | Team |
3 more people are available in the full profile.
Complete people profiles for Sherlock Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sherlock Biosciences
Sherlock Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Sense Biodetection.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of point of care molecular diagnostics solutions | sense-bio.com | Abingdon, United Kingdom | 2014 | Feb 2023 | •••• |
Complete acquisition details for Sherlock Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sherlock Biosciences
5 dated milestones of Sherlock Biosciences across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Sherlock Biosciences is founded.
- Funding First funding round of $31.0M.
- Acquisition Acquires Sense Biodetection.
- Funding Latest funding round, Grant, of $299K.
- Exit Acquired by OraSure.
Competitors of Sherlock Biosciences
Sherlock Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Amyris, Syngenta, AskBio and Color, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $3.22B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| syngenta.com | 2000 | Basel, Switzerland | – | – | Crop protection solutions and hybrid seeds are provided for farming. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| color.com | 2013 | Burlingame, United States | $506.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| asimov.com | 2017 | Boston, United States | $209.4M | 87 | Provider of integrated suite for advanced genetic design and manufacturing |
Detailed competitors of Sherlock Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sherlock Biosciences
The website of Sherlock Biosciences (sherlock.bio) receives about 2.8K visits a month and ranks #4,929,420 among all websites worldwide, #5,748 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▼ 20.6% vs previous month
- Unique visitors1.5K
per month
- Global rank#4,929,420
among all websites
- Category rank#5,748
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit21 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Sherlock Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cuebiopharma.com | 100% | 4.9K | #7,063,180 | View details | |
| dynotx.com | 99% | 14.4K | #2,089,404 | View details | |
| ornatx.com | 98% | 4.4K | #3,250,511 | View details | |
| dayzerodiagnostics.com | 98% | 1.4K | #5,790,285 | View details | |
| lyndra.com | 95% | – | #9,629,878 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Sherlock Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Sherlock Biosciences
Complete news archive for Sherlock Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sherlock Biosciences
10 companies that operate in the same segment as Sherlock Biosciences (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sherlock Biosciences
Sherlock Biosciences was founded in 2019.
Sherlock Biosciences is headquartered in Watertown, United States.
Bryan Dechairo is the current CEO of Sherlock Biosciences.
Sherlock Biosciences is a funded company, having raised a total of $111M across 8 funding rounds to date. The company's 1st funding round was a Series A of $31M, raised on Apr 2019.
Sherlock Biosciences has 33 employees.
Sherlock Biosciences, a subsidiary of OraSure Technologies, is dedicated to the development of molecular diagnostics using CRISPR and synthetic biology. The company is engaged in creating rapid, accurate, and affordable diagnostic tools through proprietary platforms like SHERLOCK and INSPECTR. Solutions are designed for point-of-need testing to democratize and decentralize healthcare. The focus is on personalizing healthcare and impacting global health by enabling accessible diagnostic answers in various settings.
Sherlock Biosciences offers SHERLOCKâ„¢ and INSPECTRâ„¢.
Sherlock Biosciences has made 1 acquisition, including Sense Biodetection.
Sherlock Biosciences has 11 investors. Key investors include United States Department of Agriculture, Gates Foundation, OraSure Technologies, Novalis LifeSciences, and Illumina Ventures.
Sherlock Biosciences operates through Orasure Technologies, Inc..
Yes. Sherlock Biosciences was acquired by OraSure in December 2024.